Home > Our Professionals > Lipsey, Charles E. > News

Charles E. Lipsey
571.203.2755
charles.lipsey@finnegan.com

Two Freedom Square
11955 Freedom Drive
Reston, VA 20190-5675
571.203.2700
Fax 202.408.4400

Download vCard

Bar and Court Admissions

District of Columbia
Virginia
U.S. Court of Appeals, Federal Circuit
U.S. Patent and Trademark Office

Education

George Washington University, National Law Center
LL.M., Patent and Trademark Regulation Law, with highest honors, 1981
George Washington University Law School
J.D., high honors, 1977
Georgia Institute of Technology
B.S., Chemical Engineering, 1972

Judicial Clerkships

Charles E. Lipsey

Partner

Profile | Articles | Speaking Engagements | IP Updates | News

May 24, 2013	Chambers USA Continues to Rank Finnegan as a Band One IP Law Firm
April 1, 2013	Cephalon Beats Challenge to Narcolepsy Drug Patent
March 30, 2013	District Court Rules in Favor of Finnegan Client Cephalon to Uphold Patent for Nuvigil®
March 25, 2013	Actavis, AstraZeneca Settle Crestor® Generic Suit
March 25, 2013	AstraZeneca Reaches Deal with Generics over Crestor® Patent
March 19, 2013	Managing Intellectual Property Recognizes Finnegan Life Sciences and Trademark Practices
February 8, 2013	AstraZeneca, Torrent Settle Time-Release Seroquel® IP Row
December 11, 2012	Lilly Sues USPTO for Extra 1.5 Years on Cancer Patent
September 24, 2012	District of Delaware Rules in Favor of Finnegan Client Galderma Laboratories
August 1, 2012	Another Co. Surrenders in Seroquel XR® Patent Fight
June 13, 2012	Intellectual Asset Management Magazine Recognizes Finnegan and 18 Finnegan Partners as Leading Patent Practitioners
June 7, 2012	Chambers USA Recognizes Finnegan as a Band One Intellectual Property Law Firm
June 6, 2012	The Legal 500 U.S. Continues to Rank Finnegan as a Tier One Intellectual Property Law Firm
June 1, 2012	LMG Life Sciences Ranks Finnegan as a Highly Recommended Firm for Life Sciences Patent Work
June 1, 2012	America’s Best Life Sciences Litigators
April 20, 2012	Jury Verdict in Favor of Firm Client Avid Radiopharmaceuticals
January 3, 2012	The American Lawyer Names Finnegan as Intellectual Property Litigation Department of the Year
January 2, 2012	Patently Driven
December 2011	Washington’s Best Lawyers
December 1, 2011	Fed. Circ. Keeps Teva Out of Luck Over Crestor®
September 29, 2011	AstraZeneca, Handa Settle Seroquel® Patent Fight
September 2, 2011	Twenty-Two Finnegan Lawyers Named "The Best Lawyers in America" for 2012
July 29, 2011	Federal Circuit Reverses District Court Ruling of Invalidity and Upholds Rulings on Other Grounds in Favor of Finnegan Client Eli Lilly and Company
June 10, 2011	Finnegan Recognized as a Leading Intellectual Property Law Firm by Chambers USA for 2011
June 9 , 2011	Lilly Sues Hetero to Block Generic Strattera®
June 1, 2011	The Legal 500 U.S. Ranks Finnegan Among Top Firms in IP for 2011
May 25, 2011	AstraZeneca Adds Intellipharmaceutics to Seroquel® Row
May 10, 2011	Intellectual Asset Management Magazine Recognizes Finnegan and Nine Finnegan Partners as Leading Patent Litigators for 2011
May 9, 2011	Lilly Claims Zydus Broke Deal In Strattera® Row
April 28, 2011	Finnegan Client Eli Lilly and Company Prevails in U.S. Cymbalta® Litigation
January 5, 2011	IP Group of the Year: Finnegan
December 2, 2010	AstraZeneca Seeks to Halt Mylan's 2nd Seroquel® ANDA
October 21, 2010	District Court Grants Summary Judgment in Favor of Finnegan Client AstraZeneca
September 1, 2010	U.S. Court of Appeals for the Federal Circuit Rules in Favor of Finnegan Client Eli Lilly and Company, Affirming the Validity of Eli Lilly’s Patents for Evista®
August 4, 2010	Twenty-Two Finnegan Lawyers Named "The Best Lawyers in America" for 2011
July 1, 2010	District of Delaware Rules in Favor of Finnegan Clients AstraZeneca and Shionogi Pharmaceuticals, Finding that Patent Covering Crestor® is Valid and Enforceable
June 17, 2010	Finnegan Recognized as Top-Tier Intellectual Property Law Firm by Chambers USA for 2010
March 24, 2010	En Banc Court Confirms Section 112’s Separate Written Description Requirement
March 23, 2010	Full Federal Circuit Holds Written Description and Enablement Are Separate Requirements
March 22, 2010	Federal Circuit Rules in Favor of Finnegan Client Eli Lilly and Company, Confirming the Existence of a Separate Written Description Requirement
February 22, 2010	AstraZeneca Begins Court Fight Over Crestor® Patent
January 7, 2010	Interpreting Oral Arguments in Ariad v. Eli Lilly
December 11, 2009	"Possession" Test is Focus of Arguments in Written Description Requirement Appeal
December 2009	Washington's Top Lawyers
September 30, 2009	Eli Lilly and Company Wins Challenge to Patents Covering its Osteoporosis Drug, Evista®
July 30, 2009	Twenty-Two Finnegan Lawyers Named Best Lawyers in America
April 27, 2009	Court Grants Lilly Request, Blocks Teva Evista® Copy: Teva Plans to Appeal Decision
February 27, 2009	Extension of 30-Month ANDA Stay Affirmed When Generic Product Modified During Stay
February 26, 2009	Federal Circuit Hits Teva, Loeb & Loeb for Missed Discovery Deadline
February 10, 2009	Enablement, Preempting Laws of Nature Key Issues in Ariad v. Lilly Oral Argument
October 7, 2008	Fifteen Finnegan Lawyers Named “The Best Lawyers in America”
January 5, 2007	Lilly’s Zyprexa® Drug For Schizophrenia Is Infringed By Generics And Not Invalid
January 2, 2007	Inadmissible Legal Business
September 5, 2006	Fifteen Finnegan Lawyers Named "The Best Lawyers in America"
September 2006	Billion Dollar Babies: How Big Pharma Keeps Its Blockbuster Drugs Safe
April 10, 2006	2006 Leading Lawyers--Life Sciences: Counsel on the Cutting Edge
April 6, 2006	Twelve Finnegan Henderson Lawyers Named “The Best Lawyers in America”
May 28, 2004	Finnegan to Release 2004 Biotechnology Innovation Report at BIO 2004
January 26, 2004	Eli Lilly & Co. Patent Infringement Trial over Zyprexa® Begins in Indiana

Bar and Court Admissions

Education

Judicial Clerkships

Charles E. Lipsey

Partner

Practice

Industry